Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Azelis posts resilient Q1 as acquisitions mask organic slowdown and cash flow strengthens

Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance

Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland

Move aligns global biologics identity under the Biocon Biologics brand

Merck doubles down on cardio-pulmonary breakthroughs

At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor

Amcor launches ultra-light Shadow roll-on for next-gen beauty branding

The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole